Effect of butyrate and Lactobacillus GG on a butyrate receptor and transporter during Campylobacter jejuni exposure.
Campylobacter jejuni frequently infects humans causing many gastrointestinal symptoms, fever, fatigue and several long-term debilitating diseases. Current treatment for campylobacteriosis includes rehydration and in some cases, antibiotic therapy. Probiotics are used to treat several gastrointestinal diseases. Butyrate is a short-chain fatty acid known to promote intestinal health. Interaction of butyrate with its respective receptor (HCAR2) and transporter (SLC5A8), both expressed in the intestine, is associated with water and electrolyte absorption as well as providing defense against colon cancer and inflammation. Alterations in gut microbiota influence the presence of HCAR2 and SLC5A8 in the intestine. We hypothesized that adherence and/or invasion of C. jejuni and alterations in HCAR2 and SLC5A8 expression would be minimized with butyrate or Lactobacillus GG (LGG) pretreatment of Caco-2 cells. We found that both C. jejuni adhesion but not invasion was reduced with butyrate pretreatment. While LGG pretreatment did not prevent C. jejuni adhesion, it did result in reduced invasion which was associated with altered cell supernate pH. Both butyrate and LGG protected HCAR2 and SLC5A8 protein expression following C. jejuni infection. These results suggest that the first stages of C. jejuni infection of Caco-2 cells may be minimized by LGG and butyrate pretreatment.
Pediatric Research Center, Department of Gastroenterology, Pediatrics Institute and Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, OH 44195, USA.
Gail A M
GAM
Cresci
Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.
Paul C
PC
Mayor
Department of Medicine, Division of Infectious Diseases, Augusta University, Augusta, GA 30912, USA.
Stuart A
SA
Thompson
D001422:Bacterial Adhesion / Q000187:drug effects; D002087:Butyrates / Q000378:metabolism* / Q000494:pharmacology*; D018938:Caco-2 Cells; D002169:Campylobacter Infections / Q000235:genetics / Q000378:metabolism / Q000382:microbiology; D016123:Campylobacter jejuni / Q000502:physiology*; D002352:Carrier Proteins / Q000378:metabolism*; D002478:Cells, Cultured; D015870:Gene Expression; D006801:Humans; D006863:Hydrogen-Ion Concentration; D052201:Lacticaseibacillus rhamnosus / Q000187:drug effects* / Q000378:metabolism*; D056265:Microbial Interactions; D027501:Monocarboxylic Acid Transporters / Q000235:genetics / Q000378:metabolism; D043562:Receptors, G-Protein-Coupled / Q000235:genetics / Q000378:metabolism; D011978:Receptors, Nicotinic / Q000235:genetics / Q000378:metabolism
D002087:Butyrates; D002352:Carrier Proteins; C530636:HCAR2 protein, human; D027501:Monocarboxylic Acid Transporters; D043562:Receptors, G-Protein-Coupled; D011978:Receptors, Nicotinic; C476760:SLC5A8 protein, human
Caco-2; Campylobacter jejuni; Lactobacillus GG; butyrate